US crackdown on Chinese biotech opens opportunities for Indian companies

18 June 2024
india_mumbai_large

The recent US crackdown on Chinese biotech companies marks a significant shift in the global biotechnology landscape, with profound implications for competitive strategies.

The move, driven by concerns over intellectual property theft, data privacy, and national security, has led to increased scrutiny and sanctions on Chinese biotech firms. This regulatory tightening is creating a vacuum in the biotech sector, presenting an opportunity for biotech companies from other countries, particularly India, to step in and fill the gap, reports The Pharma Letter’s India correspondent.

The BIOSECURE Act aligns with China's accelerated regulatory reforms, which streamline drug approvals and attract global companies and investors. However, geopolitical tensions have prompted global drug majors to reassess their dependence on Chinese suppliers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars